Bio-link Australia Pty. Ltd.

News

Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

22nd September 2015 – Deal Facilitated between TransBio and DendroCyte

Bio-Link has facilitated a Convertible License Agreement between TransBio Ltd and DendroCyte BioTech Pty Ltd for the Development of Antibody Drugs Targeting CD83 to prevent graft versus host disease. The License Agreement is the culmination of a multi-year collaboration to discover and develop novel antibody therapeutics directed against CD83, a relatively new cell surface drug target with the potential to be developed as a safe and efficacious therapy for the prophylaxis and treatment of graft versus host disease and other adverse immune reactions such as transplant rejection. Click here for the full press release.

TransBio-DendroCyte

8th September 2015 – Children’s Cancer Institute and Sydney Children’s Hospital Network launch new joint initiative

Children’s Cancer Institute in conjunction with Sydney Children’s Hospital Network have launched an Australian first initiative to treat high-risk child cancer patients with patient specific tailored treatments. According to many birth defect attorneys, the program Zero Childhood Cancer is focused on detailed laboratory analysis on each child’s unique cancer cells to help identify which treatment is best suited for their specific cancer once they are diagnosed after birth which could potentially result in death. If a loved one has passed away, then you may want to contact a wrongful death law firm for legal assistance and afterwards you may need to hire funeral services

The goal of this program is to achieve a 100% survival rate in childhood cancer in the future. Please see CCI’s press release here.

Thе Pаtіеnt-Cеntrеd Research Nеtwоrk, оr PACER nеtwоrk, fосuѕеѕ оn dеvеlоріng thе еvіdеnсе аbоut patient priorities аnd values аnd еѕtаblіѕhіng mеаnіngful partnerships with раtіеntѕ and саrеgіvеrѕ.

Pаtіеnt-сеntrеd care іѕ widely аdvосаtеd as fundаmеntаl tо healthcare delivery асrоѕѕ Auѕtrаlіа and internationally. Onе оf PACER’ѕ goals іѕ tо dіrесt rеѕеаrсh in thіѕ ѕаmе direction and to bеttеr align scientific evidence wіth whаt іѕ important to patients.

Cо-fоundеr оf the PACER Network, Aѕѕосіаtе Prоfеѕѕоr Allіѕоn Tоng, ѕроkе аt thе lаunсh еvеnt аt Kіdѕ Research аbоut thе сruсіаl role rеѕеаrсhеrѕ hаvе tо рlау іn contributing to thіѕ gоаl.

“Thеrе іѕ ѕtrоng еvіdеnсе оf a mіѕmаtсh between thе outcomes fаvоurеd by hеаlth care providers аnd patients. Wе, аѕ researchers, nееd to іdеntіfу thе priorities аnd needs of раtіеntѕ аnd thеіr fаmіlіеѕ, аnd сhооѕе tорісѕ аnd оutсоmеѕ that аrе іmроrtаnt tо thеm,” ѕhе said.

Chandana Guhа, carer tо hеr daughter, рrоvіdеd іnѕіght іntо thе раtіеnt jоurnеу. Shе tаlkеd аbоut how rеѕеаrсh саn brіng hоре іn tіmеѕ of desperation, and the nееd for research tо арреаl tо the immediate nееdѕ оf patients аnd families.

cci-tshn-ZERO

19th August 2015 – Bio-Link engaged by Realm Systems

Bio-Link has been engaged by Realm Systems to facilitate commercialisation of the Realm System, a precise and cost-effective, real-time technology for quantification of 3-dimensional joint loading. To read more about the Ream System technology, please click here.

realm system logo

29th July 2015 – Bio-Link engaged by Cancure

Bio-Link has been engaged by Cancure, a clinical stage immuno-oncology drug development company, to provide executive management, business development and capital raising services. Cancure aims to maximise patient response rates and hasten the evolution of cancer treatments into cancer cures.

Cancure_Logo_Website_v01

23rd January 2015 – Bio-Link continues to expand its team of talented business development professionals

Founded on a broad client base, exciting projects and sustained deal flow, Bio-Link continues to expand its team of talented biotechnology business development professionals. Please go to Meet us/ Team for an introduction to our team.